Abstract Alzheimer's disease (AD) is a multifactorial disease of wide clinical heterogenity. Overproduction of amyloid precursor protein (APP) and accumulation of β-amyloid (Aβ) and tau proteins are important hallmarks of AD. The identification of early pathomechanisms of AD is critically important for discovery of early diagnosis markers. Decreased brain metabolism is one of the earliest clinical symptoms of AD that indicate mitochondrial dysfunction in the brain. We performed the first comprehensive study integrating synaptic and non-synaptic mitochondrial proteome analysis (two-dimensional differential gel electrophoresis (2D-DIGE) and mass spectrometry) in correlation with Aβ progression in APP/PS1 mice (3, 6, and 9 months of age). We identified changes of 60 mitochondrial proteins that reflect the progressive effect of APP overproduction and Aβ accumulation on mitochondrial processes. Most of the significantly affected proteins play role in the mitochondrial electron transport chain, citric acid cycle, oxidative stress, or apoptosis. Altered expression levels of Htra2 and Ethe1, which showed parallel changes in different age groups, were confirmed also by Western blot. The common regulator bioinformatical analysis suggests the regulatory role of tumor necrosis factor (TNF) in Aβ-mediated mitochondrial protein changes. Our results are in accordance with the previous postmortem human brain proteomic studies in AD in the case of many proteins. Our results could open a new path of research aiming early mitochondrial molecular mechanisms of Aβ accumulation as a prodromal stage of human AD.
Introduction
Neurodegenerative disorders such as Alzheimer's, Parkinson's, Huntington's disease (AD, PD, HD), and prion diseases show several high importance similarities, including neuronal loss and aggregation of disease-specific misfolded proteins in the brain. These disorders belong to the family of "protein conformational" diseases [1] . Overlapping of the misfolded proteins is typical in neurodegenerative diseases: multiple toxic proteins are accumulated in AD and other age-related disorders [2] . Formation and accumulation of misfolded proteins demonstrate that failure in ATP production, protein folding, and quality control may play an important role in the pathological processes [3] . Precipitation of two main proteins (β-amyloid/Aβ and hyperphosphorylated tau) is typical in AD brain.
There are two main forms of AD: the early onset/familial and the late onset/sporadic form. Familial AD is caused by mutations of the amyloid precursor protein (APP) and the γ-secretase complex (presenilin-1 and presenilin-2/PS1 and 2) [4] . On the basis of clinical presentation, there are several further subtypes of AD (amnestic, pure amnestic, language, visuoperceptive, and executive variants) [5] . All subtypes of AD share common pathological hallmarks like the presence of amyloid plaques and neurofibrillary tangles. Consequently, amyloidogenic APP processing and tau hyperphosphorylation must be key events in the progress of AD.
Formation of amyloid plaques in the brain is also a frequent hallmark of aging without dementia [6] . It has been more and more accepted that Aβ accumulation itself is not necessarily the initial step of AD [7] , only a consequence of preceding molecular events. However, Aβ accumulation is still an important issue in AD progression, because intracellular Aβ has toxic effects in synaptic transmission and memory trace formation as well as decreases the number of synapses [8] .
The early Aβ accumulation-induced molecular mechanisms cannot be studied in humans due to ethical problems of brain biopsy, and thus, animal models should be used. One of the best models is the double transgenic A P P / P S 1 m o u s e , e x p r e s s i n g b o t h t h e h u m a n Swedish-mutant APP and a mutant PS1 [9, 10] . Cleavage of APP by β-and γ-secretase generates both Aβ and APP intracellular domain (AICD) peptides [11] ; therefore, beside Aβ accumulation, AICD peptide level also increases in APP/PS1 mice. These animals reproduce a common process in most variants of AD. APP/PS1 mice also reproduce some symptoms of AD, such as the age-dependent synaptic dysfunction and memory loss [9, 12] as well as metabolic changes due to mitochondrial dysfunction [6, 8, 10] , which are characteristic for human AD as well.
It has been revealed that overproduced APP and Aβ are present in the mitochondria of APP transgenic mouse models and human AD brain [13] [14] [15] . The presence of mitochondrial Aβ correlates well with mitochondrial dysfunction in the synapses [16] because synaptic mitochondria are particularly sensitive to Aβ [17] . Aβ is present in the synaptic mitochondria of APP/PS1 transgenic mice at early stage, when no accumulation of extracellular Aβ can be detected [17] .
Mitochondrial failure and dysfunction are an early sign of AD and other neurodegenerative disorders [10, [18] [19] [20] . Brain hypometabolism and progressive decrease of brain metabolism are the earliest clinical symptoms of AD [1] . Selection of high-risk potential AD groups of aging humans, before manifestation of cognitive impairment, represents an important aim of AD research. Changes in the level of individual mitochondrial proteins could serve as early metabolic markers for AD. Because of limitations of human studies, a necessary compromise could be the use of the double transgenic APP/PS1 mouse as a proper model for studying early molecular mechanisms of AD.
Mitochondrial proteome changes in AD models [21] [22] [23] [24] and the postmortem brain human proteomics data of AD [25] [26] [27] [28] [29] confirm the possibility of early mitochondrial protein markers for AD. However, the already published mitochondrial proteomics data are incoherent because of using different animal models and different time points of investigation in AD development. Therefore, a coherent, comprehensive study of synaptic and non-synaptic mitochondrial proteome of animal model of AD is needed to reveal early molecular mechanisms of AD. Our aim was to conduct a systematic study of proteome changes in synaptic (sMito) and non-synaptic mitochondria (nsMito) of APP/PS1 mice at different ages.
The present study focuses on two major questions: (i) Are there Aβ-induced mitochondrial proteome changes as early as 3 months of age in APP/PS1 mice without behavioral changes? (ii) How do the synaptic and/or non-synaptic mitochondrial proteomes change in the time frame of 3 to 9 months of age?
Methods

Animal Model
The APP/PS1 mice carry the Mo/Hu APP695swe (695-amino acid isoform of human APP) and PS1-dE9 (mutant human PS1) mutations. PS1-dE9 alters the specificity of γ-secretase to favor production of Aβ 42 and consequently shifts the ratio of Aβ 40 /Aβ 42 . Experiments begun with 3-month-old animals without amyloid deposits and behavioral changes. Aβ deposits appear at 6 months of age mostly in the cerebral cortex, while the amyloid plaques are abundant in the hippocampus and cerebral cortex at 9 months of age [30] . Performance of APP/PS1 mice in the Morris water maze gradually declines between 3 and 12 months of age [31] . Therefore, we selected 3-, 6-, and 9-month-old APP/PS1 and C57BL/6 (B6) control mice for proteomics (n = 36) and light microscopy experiments (n = 12). Handling and experimentation on animals were performed in conform to Council Directive 86/609/ EEC, the Hungarian Act of Animal Care, and the Experimentation (1998, XXVIII) and local regulations for care and use animals for research.
β-Amyloid Progression Detection in 3-, 6-, and 9-Month-Old APP/PS1 Mice Brain All reagents used for microscopy were obtained from Sigma-Aldrich. Twelve mice were used for microscopic investigations (two mice per group). Brains were transcardially perfused with saline then with 4 % formaldehyde, 0.05 % glutaraldehyde, and 0.2 % saturated picric acid in 0.1 M phosphate buffer (pH = 7.4; PB) for 25 min. The brains were left in the skull overnight. Blocks containing the dorsal hippocampus were sectioned at 50 μm with a vibratome VT 1000S (Leica) and stored in 0.1 M PB supplemented with 0.05 % sodium azide. Sections were washed with 0.1 M Na-cacodylate and postfixed in reduced osmium (0.5 % osmium tetroxide, 0 . 7 5 % p o t a s s i u m h e x a c y a n o -f e r r a t e i n 0 . 1 M Na-cacodylate) for 60 min, en bloc stained with half-saturated aqueous uranyl acetate, dehydrated, and flat embedded on slides in Durcupan resin (Fluka). Sections were photographed with a Zeiss Axio Imager Z1 microscope (Zeiss) equipped with a Cc1 camera.
For electron microscopy, the coverslips were removed, and small pieces from the somatosensory cortex and dorsal hippocampus were re-embedded. Ultrathin sections (70 nm) were collected on 300-mesh copper grids and stained with uranyl acetate for 5 min and lead citrate for 30 s. Grids were examined in JEOL JEM 1011 electron microscope (JEOL) operating at 60 kV. Images were taken with an Olympus Morada 11-MP camera (Olympus) and iTEM software (Olympus).
Isolation of Synaptic and Non-synaptic Mitochondria
Metabolically active sMito and nsMito were isolated according to our already published protocol [32] . Briefly, mice were decapitated and the brains rapidly removed, washed in artificial cerebrospinal fluid (ACSF), and immediately cooled in dry ice. Brain tissue (weighing 200 mg per animal) was homogenized in 700 μL of ice-cold isolation buffer (225 mM mannitol, 75 mM sucrose, 20 mM HEPES-KOH, 1 mM EGTA, protease and phosphatase inhibitor cocktails, pH adjusted to 7.2 with KOH) using pre-chilled Dounce homogenizer (Kontes Glass Co.; eight-stroke large clearance + eight-stroke small clearance). All steps were performed at 4°C or on ice with ice-cold buffers and solutions. The resultant homogenates were centrifuged at 1300g for 5 min. Supernatants were collected, and an equal volume of 30 % Percoll in isolation buffer was added. The resultant homogenate was layered with 1-mL syringe (Tuberculin, 0.5 × 25-mm needle) on a discontinuous Percoll gradient (with the bottom layer containing 40 %, followed by a 24 %, and, finally, the sample in 15 % Percoll solution) and centrifuged at 34,000g for 8 min. After centrifugation, band 2 (the interface between 15 and 23 % containing synaptosome) and band 3 (the interface between 23 and 40 % containing nsMito) were collected from the density gradient, using a tight bore medical needle (26 gauge) and a 2-mL syringe. The samples were transferred to another centrifuge tube by manually pushing through again in the same tight bore needle with high speed. As the synaptosomal fraction was getting through the needle, it became fractured by the sheer force and the internal synaptic mitochondria were released. The samples were diluted with four volumes of isolation buffer and centrifuged at 34,000g for 8 min. The resultant loose pellets containing exclusively the sMito or nsMito were collected and washed at 8000g for 15 min. The final sMito and nsMito pellets were precipitated overnight in ice-cold acetone. The electron microscopic and fluorescence-activated cell sorting (FACS) validation of sMito and nsMito samples have already been published [32] .
Proteomic Analysis by 2D-DIGE
The detailed two-dimensional differential gel electrophoresis (2D-DIGE) protocol has been described in our earlier studies [32, 33] . We used 2D-DIGE Saturation Labeling method. Equipment and software were supplied from GE Healthcare, Little Chalfont, UK. Briefly, acetone-precipitated mitochondrial samples were resuspended in a lysis buffer containing 7 M urea, 2 M thiourea, 4 % CHAPS, 20 mM Tris, and 5 mM magnesium-acetate. The pH was adjusted to 8.0, and the protein concentrations were determined by 2D-Quant Kit. Samples of 5 μg were labeled by using CyDye DIGE Fluor Saturation Labeling Kit according to the manufacturer's instructions. The sMito and nsMito samples were labeled with Cy5, and the internal standard (pool of equal amounts of all samples within the experiment) was labeled with Cy3. The two differently labeled protein samples were merged, and 12 mixtures (six-six gels simultaneously) were run. Isoelectric focusing was performed on 24-cm immobilized pH gradient (IPG) strips (pH 3-10 NL) for 24 h in an Ettan IPGphor instrument, to attain a total of 80 kVh. The applied voltages were as follows: 30 V for 3-h step, 500 V for 5 h gradient, 1000 V for 6 h gradient, 8000 V for 3 h gradient, and 8000 V for 6-h step mode. Focused proteins were reduced in equilibrating buffer containing 6 M urea, 50 mM Tris (pH 8.8), 30 % (v/v) glycerine, 2 % (w/v) sodium dodecyl sulfate (SDS), Bromophenol Blue (trace), and 1 % (w/v) mercaptoethanol for 20 min. Subsequently, the IPG strips were loaded onto 10 % polyacrylamide gels (24 × 20 cm), and SDS-PAGE was performed using an Ettan DALT Six System. Gels were scanned in a Typhoon TRIO+ scanner selecting appropriate lasers and filters. Gel images were visualized by ImageQuant TL software.
Differential protein analysis was performed using DeCyderTM 2D software 7.0 Differential In-gel Analysis (DIA) and Biological Variance Analysis (BVA) modules. The internal standard sample was the same in all gels, and fluorescent intensity changes of protein spots were normalized to the values of the corresponding internal standard. It provided an image, against which, all other gel images were normalized. Independent Student's t test was performed to determine the statistical significance of the protein abundance changes for each protein spot.
Preparative 2D Gel Electrophoresis for Protein Identification
For the identification of proteins in spots of interest, preparative 2D gel electrophoresis was performed, separately, using a total of 800 μg of proteins per gel. Resolved protein spots were visualized by Colloidal Coomassie Blue G-250 (Merck, Darmstadt, Germany).
Protein Identification by Mass Spectrometry (nanoUHPLC-MS/MS)
Digested protein samples were analyzed on a Waters n a n o A C Q U I T Y U P L C s y s t e m c o u p l e d w i t h a Micromass Q-TOF premier mass spectrometer. The samples (5-μL full-loop injection) were initially transferred with an A eluent to the pre-column at a flow rate of 10 μL/min for 1 min. Mobile phase A was 0.1 % formic acid in water whilst mobile phase B was 0.1 % formic acid in acetonitrile with 350 nL/min flow rate which were applied on a Waters BEH130 C-18 75 μm × 250 mm column with 1.7-μm particle size C-18 packing. The linear gradient was as follows: 3-10 % B over 0-1 min, 10-30 % B over 1-20 min, and 30-100 % B over 20-21 min, and the composition was maintained 100 % B for 1 min and then returned to 3 % during 1 min. The column was re-equilibrated at initial conditions for 22 min. The column was maintained at 45°C. The mass spectrometer operated in DDA mode with lock mass correction, with a nominal mass accuracy of 3 ppm. The instrument was operated in positive ion mode, performing full-scan analysis over the m/z range 400-1990 at 1/1 spectra/s for mass spectrometry (MS) and in MS/ MS. The source temperature was set at 85°C, and nitrogen was used as the desolving gas (0.5 bar). Capillary voltage and cone voltage were maintained at 3.3 kVand 26 V, respectively.
Data were processed by the WATERS ProteinLynx Global Server 2.4 software using default settings. Database search was performed by Mascot 2.2 (Matrix Science, London, UK) which was set up to search Swissprot database adjusted to tryptic digestion. Data were searched with 0.15-Da fragment and 30-ppm parent ion mass tolerances. Oxidation of methionine was specified as a variable modification.
Scaffold software (version Scaffold 3.62, Proteome Software Inc., Portland, OR) was used to validate MS/ MS-based peptide and protein detection. Protein identifications were accepted if the probability was higher than 95.0 % and contained at least two identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm.
Functional Clustering
Significantly altered proteins were clustered on the basis of the UniProt (http://www.uniprot.org/) and Gene Ontology (http:// geneontology.org/) databases. The proteins were clustered in groups according to their most relevant cellular functions, and roles in human AD pathology were also listed.
Bioinformatical Analysis of Mitochondrial Protein Changes
We analyzed the interactions between significantly changed mitochondrial proteins with Ariadne Genomics Pathway Studio ® 9.0 software environment (ResNet 9.0, 2010Q4, Ariadne Genomics, Inc, Rockville, MD, USA) [34] .
Common regulator and common target analysis were made for all mitochondrial protein changes (altogether sMito and nsMito at 3, 6, and 9 months of age). We selected for further analysis common regulator and target proteins, having minimum seven relationships with significantly changed mitochondrial proteins from our experimental results.
Htra2 and Ethe1 Protein Validation by WB
The highest fold differences in the altered synaptic mitochondrial proteins that showed significant protein-level changes in all three age groups were Htra2 and Ethe1; thus, we selected them for validation by Western blot. We used the same synaptic mitochondrial samples as utilized in the 2D-DIGE method. Proteins were separated by Tricine-SDS-polyacrylamide gel electrophoresis on 15 % polyacrylamide gels then transferred to HybondTM-LFP PVDF transfer membranes (GE Healthcare). The membranes were blocked with 5 % BSA in Tris-buffered saline and 0.1 % Tween 20 (TBS-T) and then washed in TBS-T. The blots were incubated with the following primary antibodies: rabbit a n t i -H t r a 2 p o l y c l o n a l a n t i b o d y ( 1 5 7 7 5 -1 -A P, Proteintech) at 1:1000 and rabbit anti-Ethe1 polyclonal antibody (ab154041; Abcam) at 1:500 dilution. Subsequently, the membranes were washed 4 × 5 min in TBS-T followed by the incubation with ECL Plex CyDye-conjugated anti-rabbit IgG secondary antibody (GE Healthcare). After washing steps in TBS-T and then in TBS, the bands were visualized using a Typhoon TRIO+ scanner. Fluorescent intensities were quantified using the ImageQuant TL software. Differences between APP/PS1 and B6 samples were statistically analyzed using Student's t test. Differences between 3-, 6-, and 9-month-old age groups were statistically analyzed using one-way ANOVA Tukey post hoc analysis.
Results
Distribution of Aβ Plaques
Our studies confirmed that 3-month-old APP/PS1 mice do not develop amyloid deposits (Fig. 1e) . The amyloid plaques appear at 6 months of age in transgenic animals (Fig. 1f) , while hippocampus and cerebral cortex show high amyloid burdens (Fig. 1g ) at 9 months of age. Mice from line B6 (controls) show no amyloid deposition throughout the aging (Fig. 1a-c) . The timing of Aβ plaque formation reproduced data known from previous studies [30, 31] . We found amyloid plaques both at light (Fig. 1d) and at electron microscopy levels (Fig. 1h) . Fig. 1 Representative light microscopy images of 3-, 6-, and 9-monthold B6 control (a-c) and APP/PS1 transgenic mice (e-g) hippocampal and cortical brain regions. White arrows indicate amyloid plaque that appears in 6-and spread in 9-month-old APP/PS1 mice brain. Highermagnification image of an amyloid plaque stained with reduced osmium (d). Low-power electron micrograph of the same amyloid plaque as shown in d (h). Scale bars: a-g 500 μm, d, h 20 μm (CA1 cornu ammonis 1, DG dentate gyrus, cc corpus callosum)
Proteomic Examination by Two-Dimensional Differential Gel Electrophoresis
2D-DIGE Spot Changes and Protein Identification by nanoUHPLC-MS/MS
We detected approximately 1200 quantitatively measurable spots per gel with 2D-DIGE (full stain labeling) in sMito and nsMito fractions from brain tissues of 3-, 6-, and 9-month-old APP/PS1 mice (altogether 6 × 12 gels). Forty-three different nsMito proteins (3 months nsMito: 21; 6 months nsMito: 30; 9 months nsMito: 25) and 42 sMito proteins (3 months sMito: 24; 6 months sMito: 19; 9 months sMito: 19) were significantly changed in APP/PS1 mice compared to B6 mice by more than 1.1-fold change (there were common proteins between different age groups). Representative 2D-DIGE gel images with differentially expressed sMito and nsMito spots are shown in Fig. 2a , e, respectively. Fold changes of fluorescence intensities between control and transgenic sMito sample spots ( Fig. 2b-d) were in the range of −1.41 to 1.80 and in the range of −2.29 to 1.52 in the nsMito samples ( Fig. 2f-h) .
Proteins of significantly changed spots (p < 0.05, Student's t test calculated in BVA module of the DeCyderTM 2D software 7.0) were identified by LC/ MS-MS analysis. We described a total of 60 different proteins (Table 1) . Several proteins were present in more than one spot suggesting posttranslational modification or the presence of protein isoforms.
Functional Clustering of Mitochondrial Protein Changes
The identified, altered proteins participate in a variety of mitochondrial processes including tricarboxylic acid (TCA) cycle (n = 11), electron transport chain (ETC) (n = 15), oxidative stress and apoptosis (n = 10), protein transport mechanism (n = 2), mitochondrial protein synthesis and folding (n = 4), glycolysis and gluconeogenesis (n = 2), nucleotide metabolism (n = 4), ketone body metabolism (n = 2), lipid metabolism (n = 2), amino acid metabolism (n = 2), lactate metabolism (n = 1), glutathione metabolism (n = 1), synaptic transmission (n = 1), signal transduction (n = 1), and others with unknown function (n = 2) ( Table 1, Fig. 3 ). We also depicted the significant synaptic (Fig. 4a ) and non-synaptic mitochondrial protein changes (Fig. 4b) on the basis of mitochondrial biochemical pathways in each age group.
Expressions of ETC proteins changed in the greatest extent. Two subunits of complex I, NADH dehydrogenase [ubiquinone] flavoprotein 2 (Ndufv2) (1.50-fold change) and NADH dehydrogenase [ubiquinone] iron-sulfur protein 8 (Ndufs8) (1.77-fold change), showed the highest protein-level changes in the 6 months of age sMito (Table 1) . Proteins belonging to the ETC showed both increased and decreased levels in APP/PS1 model in correlation with age.
The majority of proteins belonging to the TCA cycle showed downregulation at 3-month-old age, both in sMito (Fig. 4a) and nsMito (Fig. 4b) . Interestingly, at 6 months of age, most of these proteins showed increased levels, which might reflect a compensatory mechanism. In the 9-month-old late phase, TCA cycle proteins showed bidirectional changes. Among these proteins, pyruvate dehydrogenase E1 component subunit alpha somatic form (Pdha1) (1.56-fold change) and malate dehydrogenase (Mdh2) (1.72-fold change) showed the highest alterations. Expression levels of both these proteins were increased in the 6 months of age sMito, as well (Fig. 4) .
Serine protease Htra2/Omi (Htra2) and persulfide dioxygenase ETHE1 (Ethe1) showed the greatest synaptic mitochondrial protein changes involved in oxidative stress response and apoptosis. These proteins showed parallel expression level changes in the different age groups (↓↑↓). These findings were also validated with Western blot (WB) (Fig. 5) .
Bioinformatics Analysis of Mitochondrial Protein Changes
We found 17 different common regulator proteins. Based on the UniProt and Gene Ontology databases, the common regulators are important cytokines (n = 3), protein kinases (n = 3), transcription factors (n = 3), activators (n = 3), hormones (n = 2), inhibitors (n = 2), and a chaperone (n = 1) (Fig. 6a) . Regulator proteins showing remarkably high number of relationships were Sp1 (transcription factor Sp1), insulin (INS), angiotensinogen (Agt), and tumor necrosis factor (TNF) alpha (9, 10, 10, and 14 relationships, respectively, with the altered mitochondrial proteins).
We found ten different common target proteins. Based on the UniProt and Gene Ontology databases, the Fig. 2 Representative 2D-DIGE image with labeled locations of synaptic mitochondrial significant protein changes on the gel (a). Fold changes of the synaptic mitochondrial proteins of 3 (b)-, 6 (c)-, and 9-month-old animals (d). Representative 2D-DIGE image with labeled locations of non-synaptic mitochondrial significant protein changes on the gel (e). Fold changes of the non-synaptic mitochondrial proteins of 3-(f), 6-(g), and 9-month-old animals (h). All identified protein spots are circled. Pink, turquoise, and yellow circles indicate significant protein spot changes of 3-, 6-, and 9-month-old animals, respectively. The spot numbers above the circles refer to the major genes identified in the particular spot and described in Table 1 Table 1,36 -1,16 -1,12 -1,13 -1 ,10 1,31 1,24 -1,29  1,14  1,17  -1,20 1,38 1,19 -1,18 -1,27  -1,18 -1,10 1,24  -1 common target proteins are protein kinases (n = 3), caspases (n = 2), a cytokine (n = 1), an oxidoreductase (n = 1), an electron transporter (n = 1), or anti-apoptotic proteins (n = 2) (Fig. 6b) . Target proteins showing remarkably high number of relationships were glyceraldehyde-3-phosphate dehydrogenase (GAPDH), apoptosis regulator Bcl-2 (oxidoreductase BCL2), anti-apoptotic protein, and cytochrome c (Cycs) electron transporter (9, 10, and 11 relationships, respectively, with the altered mitochondrial proteins). (30) Glutathione metabolism (mitochondrion, cytoplasm)
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Glutathione S-transferase P 1 -1,49 Gstp1 gene polymorphism influence the risk of AD (109) Synaptic transmission (mitochondrion, synapse)
O55042 Snca
Alpha-synuclein -1,24
Increased Snca level in amygdala, limbic areas and inferior temporal gyrus (110; 111;
112)
Signal transduction (mitochondrion, synapse)
O55042 Pebp1
Phosphatidylethanolamine The color gradients of red (elevated protein level) to blue (reduced protein level) were used to show the differential abundances of APP/PS1 mitochondrial proteins (the numbers represent the average ratio values). Red text indicates the increased, and blue indicates the decreased protein levels in human AD brain or plasma samples (sm synaptic mitochondria, nsm non-synaptic mitochondria; 3, 6, and 9: the age of animals in months). Green indicates the proteins that are already known as binding partners of Aβ oligomer 
Validation of Htra2 and Ethe1 Protein Changes with WB
For WB analysis, sMito samples were used from APP/PS1 and B6 animals. Htra2 and Ethe1 levels were analyzed in 3-and 6-month-old sMito samples (n = 6 samples per group). The densitometry data of protein band intensities were analyzed with ImageJ software (NIH, Bethesda). The protein levels of Htra2 in 3-(0.68 ± 0.08) and 9-month-old APP/PS1 mice (0.70 ± 0.06) were significantly decreased (p < 0.001), while the protein levels of Htra2 in 6-month-old APP/PS1 mice (1.28 ± 0.07) were significantly increased (p < 0.001), compared to B6 mice. Similar to the dynamic of Htra2 protein changes, the protein levels of Ethe1 in 3-(0.74 ± 0.08) and 9-month-old APP/PS1 mice (0.68 ± 0.05) were significantly decreased (p < 0.001), while the protein levels of Htra2 in 6-month-old APP/PS1 mice (1.51 ± 0.16) were significantly increased (p < 0.001), compared to B6 mice. Thus, the WB results of these proteins confirmed the 2D-DIGE data (Fig. 5) .
The normalized Htra2 and Ethe protein levels (APP/B6 densitometric value) were significantly increased in 6-month-old compared to 3-month-old mice. Furthermore, both proteins were significantly decreased by 9 months compared to 6 months of age (p < 0.001) (Fig. 7) .
Discussion
We present here the first comprehensive study of protein network changes in sMito and nsMito at different ages of progression of APP and Aβ accumulation in APP/PS1 mice. Significant changes of 60 different mitochondrial proteins Fig. 4 Mitochondrial localization of altered synaptic (a) and non-synaptic (b) mitochondrial proteins in 3-, 6-, and 9-month-old APP/PS1 brain. Green, yellow, and orange background indicates proteins from 3-, 6-, and 9-month-old APP/PS1 animals, respectively. were identified by comparing of APP/PS1 to B6 mice ( Table 1 ). The majority of significant protein changes were related to energy metabolism (ETC and TCA cycle), oxidative stress response, and apoptosis.
Based on common regulator and target analysis of altered proteins of sMito and nsMito, we conclude that regulator and target proteins being in direct interaction with proteins changed in APP/PS1 mice are involved in inflammation and apoptotic pathways (Fig. 6 ). TNF as a common regulator and target has the highest number of relationships suggesting a pivotal role of TNF in Aβ-mediated mitochondrial protein changes in parallel with Aβ accumulation in the mitochondria. TNF is a proinflammatory cytokine, which is a key initiator of inflammation in the brain and is also involved in neurotoxicity, neuronal death, and dysfunction [35] . Increasing amount of data suggests the involvement of TNF in human AD. Aβ was found to stimulate secretion of TNF [36, 37] and other inflammatory mediators in the brain [38, 39] . Furthermore, Aβ-induced neuroinflammation is an early step in neurodegeneration [40] . In accordance with the results of animal model studies, a 25-fold elevation of TNF level was observed in the cerebrospinal fluid of AD patients [41] . TNF level is in good correlation with clinical progression of AD [42] . Inhibition of TNF signaling prevents pre-plaque Aβ-associated neuropathology [43] , while an anti-TNF therapy efficiently improved the cognition of AD patients [44] [45] [46] . Our results suggest that TNF contributes to early appearance of mitochondrial proteome changes. We raise the possibility that TNF could be an early indicator of initial phase of Aβ accumulation; however, it should be tested in human AD subjects in a non-invasive manner. The results of bioinformatics studies in APP/PS1 mice model proteomics revealed that TNF-α-induced extrinsic and Htra2-, Ethe1-, phosphatidylethanolamine-binding protein 1 (Pebp1)-, and Vdac1-related mitochondrial apoptotic pathways suggest the importance of Aβ effect on nuclear factor kappa B (NF-κB) signaling and caspase cascade pathways (Fig. 7) .
Htra2 is a member of the high-temperature requirement (HtrA) family of oligomeric serine proteases, participating in several cellular processes including mitochondrial function, autophagy, and apoptosis. Several studies have demonstrated the essential role of Htra2 in pathogenesis of Parkinson's disease [52, 53] , but its role in AD is not clear. Enzymatic activity of Htra2 increases in frontal cortex of AD patients [28] ; moreover, Htra2 accumulates in the cerebral cortex and hippocampus and is also present in senile plaques and Table 1 ). Green indicates the common regulator (a) or target (b) proteins. NFE2L2 nuclear factor erythroid 2-related factor 2, IL1B interleukin-1 beta, MAPK1 mitogen-activated protein kinase 1, TNF tumor necrosis factor, AKT1 RACalpha serine/threonine-protein kinase, APP amyloid beta A4 protein, AGT angiotensinogen, TGFB1 transforming growth factor beta-1, MYC myc proto-oncogene protein, INS insulin, PPARGC1A peroxisome proliferatoractivated receptor gamma coactivator 1-alpha, SP1 transcription factor Sp1, TP53 cellular tumor antigen p53, HSPA1A heat shock 70 kDa protein 1A/ 1B, PPARA peroxisome proliferator-activated receptor alpha, TXN thioredoxin, MAPK8 mitogen-activated protein kinase 8, CASP9 caspase-9, CYCS cytochrome c, MAPK14 mitogen-activated protein kinase 14, GAPDH glyceraldehyde-3-phosphate dehydrogenase, CASP3 caspase-3, BCL2 apoptosis regulator Bcl-2 According to [47] [48] [49] [50] [51] and own data neurofibrillary tangles [54] . Furthermore, APP is directly cleaved by the Htra2 [55, 56] . Htra2 also interacts with Aβ, contributing to its proapoptotic activity [57] . The Htra2-mediated processing of APP is a physiological process in normal brain [55] . Mitochondrial Htra2 could interact with PS1 [47, [58] [59] [60] [61] . PS1-derived peptides binding to the PDZ domain of Htra2 can induce apoptosis [47] (Fig. 7) . In conclusion, increased Htra2 level enhances Htra2-mediated APP processing that counterbalances the amyloidogenic cleavage of APP. This mechanism might slow down accumulation of Aβ in the 6-month-old APP/PS1 mice. In this way, Htra2 increase could represent a temporary protective mechanism against further Aβ overexpression at the 6-monthold mice.
Ethe1 plays an essential role in hydrogen sulfide catabolism. Ethe1 is an anti-apoptotic protein, which increases the deacetylase activity of p53 in association with histone deacetylase 1 leading to the suppression of apoptosis [62] . Ethe1 also inhibits NF-κB signaling by binding to RelA and accelerating its export from the nucleus [48] (Fig. 7) . Loss of Ethe1 causes fatal sulfide toxicity in ethylmalonic encephalopathy which is an autosomal recessive, invariably fatal disorder [63] . The role of Aβ accumulation-induced pathomechanism has not yet been described. According to our data-driven working hypothesis, the increased Ethe1 level in 6-month-old sMito might prevent Aβ-induced apoptotic processes that could be a compensatory mechanism against moderate amyloid accumulation.
Pebp1 (also known as Raf kinase inhibitor protein (RKIP)) is a multifunctional protein. It is the precursor of hippocampal cholinergic neuro-stimulating peptide (HCNP). In our study, Pebp1 showed decreased protein expression in the 9-month-old mouse only, where amyloid plaques are present in the brain. Many studies showed that Pebp1 plays a pivotal modulatory role in different signaling cascades. It inhibits the MAPK signaling pathway Ras/Raf-1/MEK/ERK by inhibition of Raf-1 phosphorylation and activation [64] and, moreover, inhibits TNF-α-induced activation of the NF-κB pathway [49] (Fig. 7) . The expression of Pebp1 mRNA was decreased in the hippocampal CA1 field in patients of late-onset AD. Since HCNP stimulates the enzymatic activity of choline acetyltransferase in neurons, its low concentration in AD patients because of its decreased precursor Pebp1 could explain the downregulation of cholinergic neurons associated with the memory loss in AD [65] . We note here that Pebp1 decreases in another AD model mouse Tg2576 in accordance with development of amyloid plaques [66] . Our data confirm importance of Pebp1 in AD pathogenesis in APP/PS1 mice model.
Voltage-dependent anion-selective channel proteins (VDACs) are pore-forming proteins found in the mitochondrial membrane of all eukaryotes and postsynaptic membranes in the brain. Our results demonstrated that Vdac1 decreased in 6-month-old APP/PS1 mice synaptic mitochondria samples, while increased in 9-month-old ones. The non-synaptic mitochondrial Vdac1 showed changes in both directions in different protein spots. VDACs regulate anion fluxes of metabolites including ATP and regulate mitochondrial metabolism. In human postmortem brains of AD subjects, Vdac1 was significantly reduced in temporal and frontal cortex and thalamus [67] . Other experiments demonstrated that Vdac1 is elevated in AD affected regions of postmortem brains and cortical tissues of APP transgenic mice. Vdac1 is linked to Aβ and phosphorylated tau in human postmortem brains of AD patients and different AD mouse models. Vdac1 increase blocks the mitochondrial permeability transition (MPT) pores, disrupts the transport of mitochondrial proteins and metabolites, impairs gating of VDAC, and causes defects in oxidative phosphorylation, leading to mitochondrial dysfunction in AD neurons [68] [69] [70] (Fig. 7) . Vdac1 is also overexpressed in the hippocampus of amyloidogenic AD transgenic mice models. Furthermore, soluble Aβ oligomers were able to induce upregulation of Vdac1 in a human neuroblastoma cell line [70] . Reduced Vdac1 expression may be beneficial to synaptic activity, may improve function, and may protect against toxicities of AD-related genes including AβPP, Tau, PS1, PS2, and BACE1 [71] . In detergent-resistant membranes, Vdac1 also associates with γ-secretase and affects Aβ production, suggesting that VDAC is a putative target for drug development against AD [72] . In conclusion, the decreased synaptic mitochondrial Vdac1 level in 6 months of age APP/PS1 mice may improve synaptic function, while increased level in older age might correlate with synaptic loss and memory impairment.
It is important to note that beside Aβ, an increasing level of AICD peptide could also mediate several processes in APP/PS1 mice. Although AICD can be generated by both α-γ and β-γ-secretase cleavages, its exact role remains controversial [73] . The AICD-mediated nuclear signaling occurs predominantly through the amyloidogenic processing pathway [74] . Moreover, AICD can interact with different intracellular adaptor proteins as signaling molecules [75] . AICD can translocate to the nucleus, forms multiprotein complexes, and regulates its own precursor's expression (APP) [76] . Furthermore, AICD acts as a positive regulator of apoptosis [77] [78] [79] and modulates inflammation-associated calcium homeostasis and ATP metabolism linked to mitochondrial bioenergetics function [80] . APP and AICD also increase the expression of mitochondrial proteins, such as mitochondrial master transcriptional coactivator PGC-1a and its target genes [81] , so APP processing may also regulate synaptic and non-synaptic mitochondrial protein changes in APP/PS1 mice.
One of the main interests of AD research nowadays is to find early markers to select and cluster high-risk people, which could be the first step for causal treatment of AD. Our results revealed some early changes of mitochondrial proteome that are present before any neurological symptoms of AD appear. To estimate the translational value of our findings, it is noteworthy that 46 out of the 60 altered proteins have already been known to change in the late stage of human AD (Table 1 /Human AD brain column, established from postmortem or autopsy confirmed AD samples). We identified 11 proteins already known as direct binding partners of human Aβ oligomers (Table 1 /green labeling) [72] , suggesting that binding of Aβ to mitochondrial proteins is a major mechanism of its metabolic action.
In summary, our results demonstrate a different and agedependent effect on synaptic and non-synaptic mitochondrial proteome in APP/PS1 mouse model of APP overproduction and Aβ accumulation. The majority of the significant protein changes were related to energy metabolism, oxidative stress response, and apoptosis. Although the levels of several mitochondrial proteins were altered at early stage, no simultaneous alteration in hydrogen peroxide generation could be detected. This indicates functional compensation of protein changes in early stage. Htra2 and Ethe1 apoptotic proteins show an age-dependent change in expression in sMito of APP/PS1 mice; thus, they could be used as progression markers of Aβ accumulation. The result of bioinformatical analysis suggests a regulatory role of TNF in Aβ-mediated mitochondrial protein changes. Our findings also suggest that the translational value of the results with mice is not negligible. Based on these findings in mice, we suggest conducting research for early tests of Htra2, Ethe1, Vdac1, Pebp1, and TNF level in further independent models (like other transgenic mammal models or mutant cell lines), together with in human CSF or plasma which could lead to the establishment of early biomarkers of high-risk population. We hope to open a new path of research aiming early mitochondrial molecular mechanisms of Aβ accumulation as a prodromal stage of human AD.
